ERBB2 and sarcoma: In a phase I clinical trial we evaluated the feasibility and safety of administering escalating doses of 2nd generation HER2-CAR (HER2.CD28.ζ-CAR) T cells for patients with recurrent/refractory HER2-positive sarcomas [5].